Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor and can have cystic components, identifiable through magnetic resonance imaging (MRI). Previous studies suggest that cysts occur in 7-23% of GBMs and report mixed results regarding their prognostic impact. Using our retrospective cohort of 493 patients with first-diagnosis GBM, we carried out an exploratory analysis on this potential link between cystic GBM and survival. Using pretreatment MRIs, we manually identified 88 patients with GBM that had a significant cystic component at presentation and 405 patients that did not. Patients with cystic GBM had significantly longer overall survival and were significantly younger at presentation. Within patients who received the current standard of care (SOC) (N=184, 40 cystic), we did not observe a survival benefit of cystic GBM. Unexpectedly, we did not observe a significant survival benefit between this SOC cystic cohort and patients with cystic GBM diagnosed before the standard was established (N=40 with SOC, N=19 without SOC); this significant SOC benefit was clearly observed in patients with noncystic GBM (N=144 with SOC, N=111 without SOC). When stratified by sex, this significant survival benefit was only preserved in male patients (N=303, 47 cystic). We report differences in the absolute and relative sizes of imaging abnormalities on MRI and the prognostic implication of cysts based on sex. We discuss hypotheses for these differences, including the possibility that the presence of a cyst could indicate a less aggressive tumor.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors would gratefully like to acknowledge the funding that made this research possible from the National Institutes of Health (R01NS060752, R01CA164371, U54CA143970, U54CA193489, U01CA220378, U54CA210180), the Arizona Biomedical Research Commission (ADHS16-162514), the James S. McDonnell Foundation (220020400TT), and the Ben and Catherine Ivy Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** co-senior authors
Addresses: LC, PW, CRR, MMM, KRS and LSH - 5777 E Mayo Blvd, Phoenix, AZ, 85054. PC - 630 West 168th Street, Mailbox 23, New York, NY 10032, GM – 13400 E Shea Blvd, Scottsdale, AZ, 85259
Author Contributions: LC and PW carried out the literature search, data analysis and manuscript preparation. CRR provided expertise in cystic GBM MRI presentation. GLM verified the statistical analyses and conclusions of this work. PC provided pathological expertise. SKJ was involved in data curation. MMM provided clinical and neuro-oncology expertise. KRS provided data, expertise, was involved in manuscript presentation and co- supervised this project. LSH provided the expertise of a neuro-radiologist, vetted data, helped in manuscript preparation and co-supervised this project. All authors have approved this manuscript for submission.
Data Availability
The data used in this study are part of a larger collection curated by one of the authors. These data contain protected health information and are therefore subject to HIPAA regulations. If requested, data may be made available for sharing to qualified parties as soon as is reasonably possible, so long as such a request does not compromise intellectual property interests, interfere with publication, invade subject privacy, or betray confidentiality. Typically, data access will occur through a collaboration and may require interested parties to obtain an affiliate appointment with the author's institution. Data that are shared will include standards and notations needed to interpret the data, following commonly accepted practices in the field.